Greg Hunt adds to March listings with melanoma extension

March 2, 2020 Latest News News of the Day

This is a preview of subscriber content

Subscribe now to continue reading.

Another cancer listing for March with health minister Greg Hunt announcing an extension to the reimbursement of Bristol-Myers Squibb's OPDIVO (nivolumab). …

Subscribe now to continue reading.

Latest Video

New Stories

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies
October 20, 2025 - - Australian Biotech
Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum
October 20, 2025 - - Australian Biotech
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 - - Australian Biotech
Biogen earns fourth 'Great Place to Work' sertification, strengthening culture of inclusion
October 20, 2025 - - Latest News
Algorae Partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand
October 20, 2025 - - Latest News
Orthocell expands stake in Marine Biomedical, secures global rights to regenerative bone technology
October 20, 2025 - - Australian Biotech
Immutep unveils dual breakthroughs at ESMO 2025, strengthening case for Efti across multiple tumour types
October 20, 2025 - - Australian Biotech

Greg Hunt adds to March listings with melanoma extension

This is a preview of subscriber content

Latest Video

Most Read

BMS says September outcome could set a new policy benchmark for access

Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access

An exceptional outcome that must not become an exception

Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer

New combination therapy sets landmark survival benchmark in bladder cancer treatment

New Stories

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies

Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum

Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome

Biogen earns fourth 'Great Place to Work' sertification, strengthening culture of inclusion

Algorae Partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand

Orthocell expands stake in Marine Biomedical, secures global rights to regenerative bone technology

Immutep unveils dual breakthroughs at ESMO 2025, strengthening case for Efti across multiple tumour types

Sign In

Greg Hunt adds to March listings with melanoma extension

This is a preview of subscriber content

Latest Video

Most Read

BMS says September outcome could set a new policy benchmark for access

Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access

An exceptional outcome that must not become an exception

Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer

New combination therapy sets landmark survival benchmark in bladder cancer treatment

Follow Us

New Stories

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies

Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum

Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome

Biogen earns fourth 'Great Place to Work' sertification, strengthening culture of inclusion

Algorae Partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand

Orthocell expands stake in Marine Biomedical, secures global rights to regenerative bone technology

Immutep unveils dual breakthroughs at ESMO 2025, strengthening case for Efti across multiple tumour types